Abstract:Recent advances in molecular diagnostics have markedly expanded our understanding of the genetic underpinnings of lymphomas and catalysed a transformation in not just how we classify lymphomas, but also how we treat, target, and monitor affected patients. Reflecting these advances, the World Health Organization Classification, International Consensus Classification, and National Comprehensive Cancer Network guidelines were recently updated to better integrate these molecular insights into clinical practice. We summarise here the molecular biomarkers of lymphomas with an emphasis on biomarkers that have well-supported prognostic and predictive utility, as well as emerging biomarkers that show promise for clinical practice. These biomarkers include: (1) diagnostic entity-defining genetic abnormalities [e.g., B-cell acute lymphoblastic leukaemia (B-ALL) with KMT2A rearrangement]; (2) molecular alterations that guide patients' prognoses (e.g., TP53 loss frequently conferring worse prognosis); (3) mutations that serve as the targets of, and often a source of acquired resistance to, small molecular inhibitors (e.g., ABL1 tyrosine kinase inhibitors for B-ALL BCR::ABL1, hindered by ABL1 kinase domain resistance mutations); (4) the growing incorporation of molecular measurable residual disease (MRD) in the management of lymphoma patients (e.g., molecular complete response and sequencing MRD-negative criteria in multiple myeloma). Altogether, our review spans the spectrum of lymphoma types, from the genetically defined subclasses of precursor B-cell lymphomas to the highly heterogeneous categories of small and large cell mature B-cell lymphomas, Hodgkin lymphomas, plasma cell neoplasms, and T/NK-cell lymphomas, and provides an expansive summary of our current understanding of their molecular pathology.

Lymphoma & Myeloproliferative Disease

Paraneoplastic Syndromes in Horses

Equine Melanoma Updates

Regression of subcutaneous lymphoma following removal of an ovarian granulosatheca cell tumor in a horse

Oral T-cell-rich large B-cell lymphoma in a horse

Multiple myeloma, immunotherapy and minimal residual disease

Canine lymphoma: clinical and hematological aspects and treatment with the Madison-Wisconsin protocol

Clinical management and susceptibility of primary hepatic lymphoma: A cases-based retrospective study

Review of Canine Lymphoma Treated with Chemotherapy—Outcomes and Prognostic Factors

The Current and Future Treatment Landscape

Equine Melanocytic Tumors: A Narrative Review

Interventions for Treatment of Cutaneous Melanoma in Horses: a Structured Literature Review

Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms

Breast leptomeningeal disease: a review of current practices and updates on management

Current Multidisciplinary Lymphoma and Myeloma Management for Surgeons

Predictive and prognostic molecular biomarkers in lymphomas

Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy

Unusual Equine Tumors

Lymphoma: The Added Value of Radiomics, Volumes and Global Disease Assessment

Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care

Research Progress of Primary Testicular Lymphoma and Primary Central Nervous System Lymphoma: Reports from the 19th European Hematology Association Annual Congress